Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

ImmunoGen Company Profile (NASDAQ:IMGN)

Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (?)
Ratings Breakdown: 1 Sell Rating(s), 6 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $10.06 (13.11% upside)

Current Analysts' Coverage Summary for ImmunoGen (NASDAQ:IMGN)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2015Canaccord GenuityReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Credit SuisseInitiated CoverageNeutral$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/1/2015ZacksUpgradeSell -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2015William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2015Cantor FitzgeraldReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015OppenheimerUpgradeMarket Perform -> Outperform$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2014JPMorgan Chase & Co.Reiterated RatingHold$13.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2014RBC CapitalLower Price TargetOutperform$18.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2014Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2014Jefferies GroupDowngradeBuy -> Hold$20.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2014Cowen and CompanyInitiated CoverageMarket Perform$8.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2014Morgan StanleyInitiated CoverageUnderweight$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/31/2014GuggenheimBoost Price Target$14.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2013Chardan CapitalReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2013Stifel NicolausDowngradeHold -> SellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/26/2013Roth CapitalInitiated CoverageBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2013 forward)